Document Detail

Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers.
MedLine Citation:
PMID:  20121289     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Rituximab is used to deplete B cells and control disease activity, mainly in patients with rheumatoid arthritis (RA) who have not responded to anti-tumor necrosis factor (TNF) therapy. Response rates and time to relapse vary significantly among treated individuals. The objective of this study was to monitor the response of seropositive and seronegative RA patients to rituximab and correlate relapse with B-cell markers in the two groups.
METHODS: Seventeen RA patients (eight seropositive for rheumatoid factor [RF+] and nine seronegative [RF-]) were treated with two cycles of rituximab. After treatment, all patients were re-evaluated at the outpatient clinic, and rituximab was readministered when disease relapse was confirmed by clinical-laboratory measures (Disease Activity Score [DAS]-28). CD20+ cells and CD20 receptor expression levels were estimated at initiation, relapse, and re-evaluation timepoints, and were compared between the two groups.
RESULTS: Seropositive patients responded favorably to treatment compared with the seronegative group. The mean time to relapse was 337.5 +/- 127.0 days for the RF+ patients versus 233.3 +/- 59.6 days for the RF- patients (p = 0.043), despite more aggressive concomitant treatment in the seronegative group. The DAS28 decrease 3 months after treatment was 1.695 +/- 1.076 in seropositive patients versus 0.94 +/- 1.62 in seronegative patients. At relapse, CD20 receptor expression (molecules/cell) was higher in RF+ patients than in their RF- counterparts, despite a significantly lower percentage of CD20+ cells.
CONCLUSION: Rituximab treatment is efficient in both seropositive and seronegative RA. However, seropositive RA patients tend to respond favorably compared with seronegative patients. The differential CD20 receptor expression in the two groups at relapse potentially suggests a different pathogenetic mechanism of relapse and merits further investigation.
Athina Pyrpasopoulou; Stella Douma; Areti Triantafyllou; Elisavet Simoulidou; Magda Samara; Efthymia Parapanisiou; Spyros Aslanidis
Related Documents :
11251689 - Drb1 alleles in polymyalgia rheumatica and rheumatoid arthritis in southern france.
11291059 - Study of human leukocyte antigen class i phenotypes in moroccan patients with nasophary...
9917959 - Pulmonary manifestations of rheumatoid arthritis.
3261029 - Complement (c3) metabolism in rheumatoid arthritis in relation to the disease course.
16142689 - Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid a...
14620159 - Lung involvement in rheumatoid arthritis.
930939 - Pharmacy program for monitoring diabetic patients.
7183609 - Percutaneous transhepatic cholangiography in sudan.
23340009 - Lipids and liver dysfunction in patients receiving parenteral nutrition.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  14     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-04-26     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  43-8     Citation Subset:  IM    
2nd Propedeutic Department of Internal Medicine, Hippokration General Hospital, Thessaloniki, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / blood,  drug therapy*,  metabolism*,  pathology
B-Lymphocytes / metabolism*
Flow Cytometry
Middle Aged
Rheumatoid Factor / blood,  physiology
Time Factors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Murine-Derived; 0/Antirheumatic Agents; 0/rituximab; 9009-79-4/Rheumatoid Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase...
Next Document:  Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus.